Discussion
CRS is a heterogeneous disease, with at least two main clinical phenotypes (CRSwNP and CRSsNP), and it is characterized by a complex interaction between the degree of upper airway inflammation (mainly Type-2) and its clinical expression; genetic, environmental and behavioral factors, together with the presence of relevant comorbidities, contribute to determine the degree of disease severity (i.e.: recurrence rate after surgery, the need of systemic corticosteroid treatment…) and the its impact on patient’s QoL and health-care related costs (Figure 2). For all these reasons, a more personalized approach, including a more precise disease endotypization, should be implemented in caring patients with CRS. In order to achieve this aim, a multidisciplinary team, including at least otolaryngologists, allegists/clinical immunologists, pulmunologists and phycologists, is mandatory (Figure 1), particularly in a era in which novel therapeutical approaches, such as biologic agents and innovative surgical treatments (i.e.: the so-called “reboot surgery”) face the scenario of CRS management.